With the help of EGFR targeting, the nanoengagers provided a robust chemoimmunotherapy platform that could recruit and activate NK cells to eliminate tumors and release cytotoxic drugs for tumor chemotherapy. This evidence concerns the gene EGFR and neoplasm.